APGE
HEALTHCAREApogee Therapeutics Inc
$84.54+1.25 (+1.50%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving APGE Today?
No stock-specific AI insight has been generated for APGE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.34$95.31
$84.54
Fundamentals
Market Cap$6.4B
P/E Ratio—
EPS$-4.22
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume414K
Avg Volume (10D)—
Shares Outstanding61.9M
APGE News
20 articles- Apogee Therapeutics Inc. (APGE): Primary Challenger to Established BlockbustersYahoo Finance·Apr 27, 2026
- Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart DataYahoo Finance·Mar 28, 2026
- Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 MillionYahoo Finance·Mar 26, 2026
- Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for InvestorsThe Motley Fool·Mar 26, 2026
- Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public OfferingGlobeNewswire Inc.·Mar 25, 2026
- APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week EfficacyYahoo Finance·Mar 24, 2026
- How Apogee, Up 20%, Plans To Take On Rival Regeneron's Eczema DrugYahoo Finance·Mar 23, 2026
- Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public OfferingYahoo Finance·Mar 23, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Mar 23, 2026
- Top Midday Stories: Trump Orders 5-Day Postponement of Strikes on Iranian Energy Sites; JPMorgan Launches $8 Billion Junk-Bond Sale for EA BuyoutYahoo Finance·Mar 23, 2026
- Apogee Therapeutics Highlights 52-Week Zumi Data, Targets 3- to 6-Month Dosing in ADMarketbeat·Mar 23, 2026
- Sector Update: Health Care Stocks Flat to Higher Pre-Bell MondayYahoo Finance·Mar 23, 2026
- Exchange-Traded Funds, Equity Futures Gain Pre-Bell Monday as Trump Declares 5-Day Pause in Iran Energy AttacksYahoo Finance·Mar 23, 2026
- Apogee strengthens case for longer-lasting eczema drugBiopharmadive·Mar 23, 2026
- Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic DermatitisYahoo Finance·Mar 23, 2026
- Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026Yahoo Finance·Mar 22, 2026
- A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price WeaknessYahoo Finance·Mar 22, 2026
- Block upgraded, Starbucks downgraded: Wall Street's top analyst callsYahoo Finance·Mar 18, 2026
- VR Adviser Adds Over 1 Million Savara SharesMotley Fool·Mar 15, 2026
- Wedbush Raises Price Target on Apogee Therapeutics (APGE)Yahoo Finance·Mar 10, 2026
All 20 articles loaded
Price Data
Open$83.88
Previous Close$83.29
Day High$84.40
Day Low$83.39
52 Week High$95.31
52 Week Low$34.34
52-Week Range
$34.34$95.31
$84.54
Fundamentals
Market Cap$6.4B
P/E Ratio—
EPS$-4.22
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume414K
Avg Volume (10D)—
Shares Outstanding61.9M
About Apogee Therapeutics Inc
Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—